Back to search results

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

Abroad (travel likely)RecruitingPHASE1

Conditions

Glioblastoma · Glioblastoma, IDH-Wildtype · Gliosarcoma · Recurrent Glioblastoma, IDH-Wildtype · Recurrent Gliosarcoma · Resectable Glioblastoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

    Contact: Study coordinator (Phioanh (. Nghiemphu) · pnghiemphu@mednet.ucla.edu · 310-825-5321
    Contact: Principal Investigator (Phioanh Nghiemphu)

  • Memorial Sloan Kettering Cancer Center, New York, New York, United States

    Contact: Study coordinator (Thomas J. Kaley) · myersl1@mskcc.org · 917-453-2968
    Contact: Principal Investigator (Thomas J. Kaley)
Study leads

  • Phioanh Nghiemphu

    Principal Investigator

    UCLA / Jonsson Comprehensive Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)